By IDSE News Staff
The FDA approved gepotidacin (Blujepa, GSK) for the treatment of female adults (≥40 kg) and children (≥12 years of age, ≥40 kg) with uncomplicated urinary tract infections (uUTIs) caused by susceptible organisms. This is the first new class of antibiotic for UTIs in nearly three decades.
It is indicated for uUTIs caused by Citrobacter freundii complex, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus.